TGFBR2 and Patent ductus arteriosus: These data are particularly relevant given that tumor cell‐specific deficiency in canonical TGFβ signaling via the loss of TGFβR2 or the downstream protein SMAD4 is common (up to 60%) in human PDA (Hahn et al, 1996; Waddell et al, 2015).